Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatoryfdatirzepatideenforcement

FDA warns public against unregistered tirzepatide product

The regulator flagged a tirzepatide product sold without registration, citing risks to consumers.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 12 05:22 ETSource: SunStar Publishing Inc.

The wire

  1. 01The FDA issued a public warning about an unregistered tirzepatide product.
  2. 02Unapproved GLP-1 products carry safety and quality risks for consumers buying outside legitimate channels.
  3. 03The source excerpt does not identify the seller or enforcement next steps.

From the source

FDA warns public against unregistered tirzepatide product

Read at news.google.com